EVENTS:   Best Equity Short Ideas Conference Call 12 - Zach Shannon/Corto Capital Advisors & Craig Huber/Huber Research Partners & Thomas Beevers /Forensic Alpha & Ed Steele/Iron Blue Financials & Bill Campbell/Paragon Intel - 12 Nov 25   Will AI Deflate the World? Macro Lessons from Three Industrial Revolutions and China - Manoj Pradhan/Talking Heads Macro - 13 Nov 25     ROADSHOWS: Forest Products Sector Equity and Commodity Research With Expertise in Distressed Debt - Kevin Mason /ERA Research   •   London   12 - 14 Nov 25       Buyside to Buyside Forum and Expert Calls across TMT, Consumer, Healthcare and Fintech - Andrew Peters /Revelare Partners   •   London   17 - 19 Nov 25       Fundamental US Healthcare Short Ideas - Dr Elliot Favus /Favus Institutional Research   •   London   17 - 19 Nov 25      

Fortnightly Publication Highlighting Latest Insights From IRF Providers

Company Research

SS&C Technologies (SSNC)

Technology

Boyar Research

Not only is SSNC trading well below precedent transactions and publicly traded comps, but with its proprietary AI technology its valuation also represents a sizeable discount to most of the other companies that are already capitalising on the AI megatrend. Boyar is also attracted to the firm’s significant recurring revenues, high margins, leading position in its field, less exposure to China, material inside ownership and strong FCF. They believe the earnings slowdown of 2022 and 2023 was a temporary lull in a longer-term growth story and therefore find the current valuation very compelling. Boyar’s intrinsic value estimate of $112 per share, offers ~80% upside.

Edition: 190

- 12 July, 2024


SS&C (SSNC)

Technology

Abacus Research

This defensive compounder offers compelling risk reward - trades at 11x EPS yet has grown EPS at a 25% CAGR for the last decade. With highly predictable earnings, SSNC is relatively well positioned into an economic downturn. Investors shouldn't focus on organic growth, earnings is driven by acquisitions and now is an opportune time with more targets available and at better prices than they have been for ages. TP $85, offers 50% upside, while Abacus Research's bearish scenario sees downside risk of only 12%.

Edition: 139

- 08 July, 2022